Evidence map›Paper›PMID 38435232›Full record

ReviewCureus2024

Ketamine in Chronic Pain: A Review.

Ana Faísco, Rita Dinis, Tânia Seixas, Luís Lopes

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Clinical applications of esketamine: Current status and future perspectives.The Journal of international medical research · 2026
    Review
  4. Review
  5. (International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ana FaíscoDepartment of Anaesthesiology, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
Rita DinisDepartment of Anaesthesiology, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
Tânia SeixasDepartment of Anaesthesiology, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
Luís LopesDepartment of Anaesthesiology, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
Hospital Prof. Dr. Fernando Fonseca · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ketamine has been used in the treatment of several pain syndromes, particularly those with a relevant neuropathic component. Sub-anesthetic doses of ketamine produce a potent analgesic effect, due to its inhibition of N-methyl-D-aspartate receptors and enhancement of descending inhibitory pathways. Its short-term analgesic effect is well-documented perioperatively, with an associated reduction in postoperative chronic pain and opioid consumption. Despite some evidence regarding its long-term benefits, the number of clinical studies is still limited. In addition to its analgesic effects, ketamine also possesses an anti-depressive action, which might be useful in the treatment of chronic pain patients. Several side effects have been described, the psychomimetic ones being the most relevant due to their impact on treatment adhesion. At present, co-administration of ketamine and benzodiazepines or α2-agonists facilitates its clinical application. Despite current evidence and increasing use, further investigation is still needed regarding its long-term safety profile and clearer risk-benefit analysis.

Indexed as

cancer painchronic painchronic postoperative painketaminenon-oncological pain

Identifiers

PMID38435232
PMCPMC10908414
OpenAlexW4391439793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.